California Public Employees Retirement System Arcus Biosciences, Inc. Transaction History

California Public Employees Retirement System

$141 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $1.95 Million - $3.07 Million	-85,700 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $206,010 - $325,946	-7,875 Reduced 8.42%	85,700 $2.41 Million
Q4 2020 Feb 02, 2021	SELL	$17.0 - $32.36 $30,600 - $58,248	-1,800 Reduced 1.89%	93,575 $2.43 Million
Q3 2020 Nov 05, 2020	BUY	$17.14 - $25.47 $365,253 - $542,765	21,310 Added 28.77%	95,375 $1.64 Million
Q2 2020 Aug 12, 2020	BUY	$13.97 - $36.56 $114,470 - $299,572	8,194 Added 12.44%	74,065 $1.83 Million
Q1 2020 May 12, 2020	BUY	$8.78 - $19.28 $31,607 - $69,408	3,600 Added 5.78%	65,871 $914,000
Q4 2019 Jan 27, 2020	BUY	$7.33 - $10.79 $312,045 - $459,341	42,571 Added 216.1%	62,271 $629,000
Q3 2019 Oct 31, 2019	BUY	$6.44 - $10.18 $35,420 - $55,990	5,500 Added 38.73%	19,700 $179,000
Q2 2019 Aug 15, 2019	BUY	$7.29 - $13.38 $23,328 - $42,816	3,200 Added 29.09%	14,200 $113,000
Q2 2018 Aug 15, 2018	BUY	$12.24 - $17.05 $134,640 - $187,550	11,000 New	11,000 $135,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

Black Rock Inc. New York, NY

9.76M
Shares

$139 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.47M
Shares

$77.7 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

3.48M
Shares

$49.4 Million
0.48% of portfolio
State Street Corp Boston, MA

3.01M
Shares

$42.8 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.44M
Shares

$34.6 Million
0.1% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.

Account